A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report

A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report

This case report describes a patient with post-neurosurgical infection and bacteremia caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae. There is limited evidence to guide antibiotic treatment decisions for such infections. The patient was treated with meropenem-vaborbact...

Full description

Bibliographic Details
Main Authors:	Seohyun Choi, Marianna Fedorenko, Janet Lin-Torre, Nirav Mistry, Steven Smoke
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	International Journal of Infectious Diseases
Subjects:	Meropenem-vaborbactam Post-neurosurgical Carbapenem-resistant enterobacterales Central nervous system Klebsiella pneumoniae carbapenemase
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971222004696

Similar Items

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
by: Shrief R, et al.
Published: (2022-10-01)

In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates
by: Jacqueline Findlay, et al.
Published: (2023-03-01)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
by: Petty LA, et al.
Published: (2018-09-01)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
by: Andrea Marino, et al.
Published: (2023-10-01)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
by: Anna Duda-Madej, et al.
Published: (2023-11-01)

A Novel KPC Variant KPC-55 in Klebsiella pneumoniae ST307 of Reinforced Meropenem-Hydrolyzing Activity
by: Eun-Jeong Yoon, et al.
Published: (2020-10-01)

Evaluation with E-test of the meropenem/vaborbactam association in carbapenem-resistant and sensitive negative control strains isolates of samples processed at the Laboratory of the Rivoli Hospital
by: Giuseppina Amarù, et al.
Published: (2022-05-01)

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant <i>Klebsiella pneumoniae</i>: A Retrospective Case Series and Literature Review
by: Alessandra Belati, et al.
Published: (2022-03-01)

Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin
by: Lorenzo Volpicelli, et al.
Published: (2024-06-01)

Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations
by: A. Oliva, et al.
Published: (2023-06-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date
by: Herald F, et al.
Published: (2023-01-01)

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing <i>K. pneumoniae</i> Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
by: Alessandra Oliva, et al.
Published: (2021-06-01)

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates
by: Dee Shortridge, et al.
Published: (2023-02-01)

In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China
by: Huang N, et al.
Published: (2021-06-01)

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections
by: Tanaya Bhowmick, et al.
Published: (2020-10-01)

In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing <i>Enterobacter cloacae</i> and <i>Klebsiella pneumoniae</i> in Murine Pneumonia Model
by: Mao Hagihara, et al.
Published: (2021-09-01)

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
by: Richard G. Wunderink, et al.
Published: (2018-10-01)

Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing <i>Klebsiella pneumoniae</i>
by: Maria V. Golikova, et al.
Published: (2023-05-01)

Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure
by: Nicholas Rebold, et al.
Published: (2023-02-01)

In Vitro Activity of New β-Lactamase Inhibitor Combinations against <i>bla</i><sub>NDM</sub>, <i>bla</i><sub>KPC</sub>, and ESBL-Producing Enterobacteriales Uropathogens
by: Lubna Razaq, et al.
Published: (2023-09-01)

The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance
by: Chiaki Ikenoue, et al.
Published: (2024-02-01)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
by: Helio S. Sader, et al.
Published: (2021-12-01)

AVALIAÇÃO DA ATIVIDADE IN VITRO DE CEFIDEROCOL, CEFTAZIDIMA/AVIBACTAM E MEROPENEM/VABORBACTAM CONTRA BACTÉRIAS MULTIRRESISTENTES OBTIDAS DE PACIENTES INTERNADOS EM HOSPITAL TERCIÁRIO NO SUL DO BRASIL
by: Patricia Orlandi Barth, et al.
Published: (2023-10-01)

Risk factors for KPC-producing Klebsiella pneumoniae bacteremia
by: Felipe F. Tuon, et al.

Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms
by: Sarah C. J. Jorgensen, et al.
Published: (2018-10-01)

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring
by: Rossella Barone, et al.
Published: (2023-04-01)

Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)
by: Tommaso Lupia, et al.
Published: (2022-10-01)

Epidemiology and clinical characteristics of patients with carbapenem-resistant enterobacterales infections: experience from a large tertiary care center in a developing country
by: Banan M. Aiesh, et al.
Published: (2023-10-01)

Exogenous glutathione reverses meropenem resistance in carbapenem-resistant Klebsiella pneumoniae
by: Juan Yi, et al.
Published: (2023-12-01)

Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
by: Keith S. Kaye, et al.
Published: (2023-02-01)

Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam
by: Siquan Shen, et al.
Published: (2022-12-01)

Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades
by: Daniele Roberto Giacobbe, et al.
Published: (2023-12-01)

In vitro activity of meropenem, imipenem, cefepime, cefoxitin and ciprofloxacin against multiresistant Klebsiella pneumoniae.
by: P Pruekprasert, et al.
Published: (2006-06-01)

Treatment of <it>Klebsiella Pneumoniae</it> Carbapenemase (KPC) infections: a review of published case series and case reports
by: Lee Grace C, et al.
Published: (2012-12-01)

Global Phylogeography and Genomic Epidemiology of Carbapenem-Resistant blaOXA-232–Carrying Klebsiella pneumoniae Sequence Type 15 Lineage
by: Yuye Wu, et al.
Published: (2023-11-01)

KPC-producing Klebsiella pneumoniae, finally targeting Turkey
by: J. Labarca, et al.
Published: (2014-03-01)

ST11 Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Clone Harboring <i>bla</i><sub>NDM</sub> Replaced a <i>bla</i><sub>KPC</sub> Clone in a Tertiary Hospital in China
by: Qiaoyan Duan, et al.
Published: (2022-10-01)

In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales
by: Zhiwei Huang, et al.
Published: (2024-04-01)